8-K: MeiraGTx Reports Positive Clinical Data and Financial Update for First Quarter 2024

MeiraGTx announced positive clinical data from its Phase 1 AQUAx study and a $50 million milestone payment, alongside its first quarter 2024 financial results.

Summary

• MeiraGTx reported its financial and operational results for the first quarter of 2024, highlighting progress in its clinical programs.
• The company presented positive data from the Phase 1 AQUAx study for radiation-induced xerostomia (RIX), showing significant improvements in patient-reported outcomes and saliva production.
• A $50 million milestone was received following the initiation of an extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec) in X-linked retinitis pigmentosa (XLRP).
• Clinical development milestones for AAV-hAQP1 for RIX, bota-vec for XLRP, and AAV-GAD for Parkinson's disease remain on track for the year.
• The company is prioritizing its riboswitch platform for metabolic diseases, demonstrating significant efficacy improvements in preclinical models.
• MeiraGTx had approximately $119.2 million in cash and cash equivalents as of March 31, 2024, which increased to $138.9 million after receiving $19.7 million in receivables in April.
• The company believes it has sufficient capital to fund operations into the first quarter of 2026, excluding potential milestones from the bota-vec program.
• Service revenue was $0.7 million for the quarter, while there was no license revenue compared to $3.3 million in the same period last year.
• Research and development expenses increased to $34.3 million, primarily due to manufacturing costs and decreased Janssen reimbursements.
• The net loss for the quarter was $20.4 million, or $0.32 per share, compared to a net loss of $30.4 million, or $0.62 per share, in the first quarter of 2023.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with significant clinical progress, a substantial milestone payment, and a promising technology platform. While there are financial losses, the company's cash runway and future milestones provide a positive outlook. The sentiment is strong due to the positive clinical data and the potential of the riboswitch platform.

Positives

• The Phase 1 AQUAx study showed statistically significant improvements in patient-reported outcomes and saliva production, with a 112.8% increase in Unstimulated Whole Saliva Flow Rate at Month 12.
• The company received a $50 million milestone payment, strengthening its financial position.
• The riboswitch platform shows promise for metabolic diseases, with significant efficacy improvements in preclinical models.
• MeiraGTx has aligned with the FDA on requirements for the Phase 2 AQUAx2 trial, potentially accelerating the path to regulatory approval.
• The company has completed dosing in the AAV-GAD bridging study and is on track for Phase 3 discussions.
• The company anticipates additional milestone payments of $15 million in 2024 and up to $285 million upon commercialization of bota-vec.
• The company has sufficient capital to fund operations into the first quarter of 2026.

Negatives

• The company reported a net loss of $20.4 million for the quarter.
• There was no license revenue for the quarter, compared to $3.3 million in the same period last year.
• Research and development expenses increased significantly to $34.3 million.
• The company experienced a foreign currency loss of $0.5 million, compared to a gain of $3.9 million in the same period last year.

Risks

• The company is incurring significant losses and may not achieve profitability.
• There is a risk of failure to obtain regulatory approval for product candidates.
• The company faces significant competition in the pharmaceutical and biotechnology industries.
• The company is dependent on third parties for manufacturing and other services.
• There are risks associated with the company's international operations.
• The company's ability to achieve milestones and receive payments is subject to various factors, including regulatory approvals and commercial success.

Future Outlook

MeiraGTx anticipates continued progress in its clinical programs, including discussions with global regulators for Phase 3 studies, and expects to receive additional milestone payments. The company is also prioritizing its riboswitch platform for metabolic diseases and plans to present data at an R&D Day in the second half of 2024.

Management Comments

• Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx, stated that the first quarter was highlighted by significant progress in the company's wholly-owned late-stage clinical programs.
• Dr. Forbes noted that the data from the Phase 1 AQUAx study was extremely encouraging, showing significant improvements in patient-reported outcomes and saliva production.
• Dr. Forbes mentioned that the company is prioritizing moving one or more incretin, myokine, and adipokine combinations towards the clinic to address obesity and metabolic disease.
• Dr. Forbes highlighted the potential of the riboswitch platform for in vivo delivery of short-acting metabolic peptides.

Industry Context

This announcement reflects the ongoing advancements in gene therapy and the increasing focus on innovative treatments for unmet medical needs. The positive data from the AQUAx study and the progress in the XLRP and Parkinson's programs position MeiraGTx as a key player in the gene therapy space. The company's riboswitch platform also represents a novel approach to drug delivery and metabolic disease treatment, which could differentiate it from competitors.

Comparison to Industry Standards

• The 112.8% increase in Unstimulated Whole Saliva Flow Rate in the AQUAx study is a significant improvement compared to existing treatments for xerostomia, which often provide only symptomatic relief.
• The $50 million milestone payment received by MeiraGTx is a substantial achievement, reflecting the value of its bota-vec program and its collaboration with Janssen, which is comparable to other significant deals in the gene therapy space.
• The company's riboswitch platform, with its ability to precisely control gene expression, is a novel approach that could provide a competitive advantage over traditional gene therapy methods.
• The company's focus on in-house manufacturing capabilities is in line with industry trends, allowing for greater control over production and cost of goods.

Related Party Transactions

• The company reported service revenue of $0.7 million from a related party, Janssen, due to progress of process performance qualification services under the asset purchase agreement.
• The company received $10.1 million from Janssen in connection with the collaboration agreement.

Stakeholder Impact

• Shareholders may view the positive clinical data and milestone payments favorably, potentially leading to an increase in share value.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with xerostomia, XLRP, and Parkinson's disease may benefit from the company's innovative therapies.
• The company's collaboration with Janssen may lead to increased revenue and market access.

Next Steps

• The company intends to continue enrolling and dosing participants in the Phase 2 AQUAx2 study.
• MeiraGTx plans to initiate Phase 3 study design discussions with global regulatory agencies for AAV-GAD in the second half of 2024.
• The company intends to present data from its riboswitch gene regulation technology platform at an R&D Day in the second half of 2024.
• MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
• The company will continue to work towards the commercialization of bota-vec and the transfer of manufacturing technology to Janssen.

Key Dates

Keywords

gene therapy, clinical trials, riboswitch, xerostomia, Parkinson's disease, retinitis pigmentosa, AAV-hAQP1, bota-vec, AAV-GAD, metabolic disease, milestone payments, biotechnology